Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
Completed
Noscira SA
Phase 1/Phase 2
The purpose of this study is to evaluate if 4 escalating doses during 20 weeks of NP031112
are safe and tolerated in patients with Alzheimer´s disease.
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Completed
i3 Research
N/A
The purpose of this study is to determine wether NP031112 is safe and effective in the
treatment of mild to moderate Progressive Supranuclear Palsy
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Completed
Noscira SA
N/A
The purpose of this study is to determine wether NP031112 is safe and effective in the
treatment of mild to moderate Progressive Supranuclear Palsy
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
Completed
ICON Clinical Research
Phase 2
The main purpose of this study is to evaluate the cognitive changes after administration of
tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in
patients with mild to moderate Alzheimer's disease.
After the 26 week core treatment period, the patients may continue in the study under blinded
conditions for an optional extension period up to a maximum of 39 additional weeks (total
study duration up to 65 weeks), until the last patient in the study has completed the 26 week
of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
